Aberrant epithelial morphology and persistent epidermal growth factor receptor signaling in a mouse model of renal

Zachary S Morris1, Andrea I McClatchey

  • 1Massachusetts General Hospital Center for Cancer Research and Department of Pathology, Harvard Medical School, Charlestown, MA 02129, USA.

Insights

NF2 deficiency in kidney cells drives cancer by activating EGFR signaling. Inhibiting EGFR with erlotinib halts tumor growth in a new mouse model, offering insights into renal cell carcinoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Nephrology

Background:

  • Epidermal growth factor receptor (EGFR) is implicated in kidney tubule hyperproliferative diseases.
  • The NF2 tumor suppressor Merlin inhibits EGFR signaling in a cell contact-dependent manner.
  • NF2 mutations are found in a small percentage of renal cell carcinoma (RCC) cases.

Purpose of the Study:

  • To investigate the roles of Merlin and EGFR in kidney tumorigenesis.
  • To develop and characterize a novel mouse model for studying RCC.

Main Methods:

  • Generated mice with targeted deletion of Nf2 in proximal convoluted epithelium using Villin-Cre.
  • Analyzed tumor progression, cell proliferation, EGFR signaling, and epithelial polarity.
  • Assessed tumor cell dependency on EGF and response to EGFR inhibition (erlotinib).

Main Results:

  • Mice lacking Nf2 in kidney epithelium developed invasive carcinoma with hyperproliferation and increased progenitor cells.
  • Early tumors showed hyperactivated EGFR signaling, altered adherens junctions, and loss of polarity.
  • Nf2-deficient kidney cells were EGF-dependent and sensitive to EGFR inhibition or Nf2 re-expression.
  • EGFR inhibition with erlotinib halted tumor cell proliferation in vivo.

Conclusions:

  • NF2 deficiency contributes to kidney tumorigenesis through EGFR hyperactivation.
  • This mouse model is valuable for studying RCC molecular mechanisms.
  • EGFR signaling is a potential therapeutic target in NF2-associated RCC.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...